April 16, 2018 / 11:10 AM / 8 months ago

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

April 16 (Reuters) - Celldex Therapeutics Inc:

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT

* CELLDEX THERAPEUTICS INC - GLEMBATUMUMAB VEDOTIN SAFETY PROFILE WAS CONSISTENT WITH PRIOR EXPERIENCE

* CELLDEX THERAPEUTICS INC - EVALUATING OUR OPERATIONAL AND WORKFORCE NEEDS TO EXTEND OUR FINANCIAL RESOURCES

* CELLDEX THERAPEUTICS INC - RANDOMIZED, PHASE 2B METRIC STUDY OF GLEMBATUMUMAB VEDOTIN COMPARED TO XELODA FAILED TO MEET ITS PRIMARY ENDPOINT

* CELLDEX THERAPEUTICS INC - NO SIGNIFICANT ADVANTAGE FOR GLEMBATUMUMAB VEDOTIN IN KEY SECONDARY ENDPOINTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below